Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | -55,68k | 77,68k | Derivative Exercise and Sale | 1,69 - 3,09 | 1,47M | - |
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | 20,81k | 35,18k | Derivative Exercise and Retained Stock | 1,69 | 1,47M | 1,44% |
| 2026-05-19 | Dr. Gaurav D. ShahCEO & Director | -2,41k | 7,26k | Vente | 3,01 | 1,45M | -0,17% |
| 2026-05-19 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -662,00 | 2,00k | Vente | 3,01 | 677,98k | -0,10% |
| 2026-05-19 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -384,00 | 1,16k | Vente | 3,01 | 89,78k | -0,43% |
| 2026-05-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -3,36k | 12,12k | Vente | 3,61 | 678,64k | -0,49% |
| 2026-05-13 | Dr. Gaurav D. ShahCEO & Director | -2,73k | 9,84k | Vente | 3,61 | 1,45M | -0,19% |
| 2026-05-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -855,00 | 3,08k | Vente | 3,61 | 90,16k | -0,94% |
| 2026-05-07 | Ms. Sarbani ChaudhuriChief Commercial & Medical Affairs Officer | -17,65k | 67,74k | Vente | 3,84 | 141,59k | -11,08% |
| 2026-02-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,16k | 3,86k | Vente | 3,34 | 91,02k | -1,26% |
| 2026-02-18 | Dr. Gaurav D. ShahCEO & Director | -5,99k | 19,99k | Vente | 3,34 | 1,45M | -0,41% |
| 2026-02-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,38k | 4,59k | Vente | 3,34 | 682,00k | -0,20% |
| 2026-02-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,25k | 40,58k | Vente | 3,31 | 121,56k | -9,16% |
| 2026-02-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -3,73k | 12,34k | Vente | 3,31 | 92,18k | -3,89% |
| 2026-02-13 | Dr. Gaurav D. ShahCEO & Director | -12,28k | 40,67k | Vente | 3,31 | 1,09M | -1,11% |
| 2026-01-02 | Dr. Elisabeth BjorkInitié | 10,00k | 34,40k | Achat | 3,44 | 20,00k | 100,00% |
| 2025-11-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,55k | 7,59k | Vente | 2,98 | 127,19k | -1,96% |
| 2025-11-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,65k | 4,91k | Vente | 2,98 | 133,82k | -1,22% |
| 2025-11-18 | Dr. Gaurav D. ShahCEO & Director | -6,28k | 18,72k | Vente | 2,98 | 1,18M | -0,53% |
| 2025-11-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,09k | 3,24k | Vente | 2,98 | 65,92k | -1,62% |
| 2025-09-19 | RTW Investments, LPSociété | -1,10M | 38,45M | Derivative Exercise and Sale | 3,11 - 40,03 | 18,19M | - |
| 2025-08-27 | Dr. Elisabeth BjorkInitié | 10,00k | 34,10k | Achat | 3,41 | 10,00k | - |
| 2025-08-18 | Dr. Gaurav D. ShahCEO & Director | -2,23k | 6,81k | Sale to Issuer | 3,05 | 1,19M | -0,19% |
| 2025-08-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,59k | 4,84k | Vente | 3,00 - 3,07 | 135,46k | -1,16% |
| 2025-08-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,06k | 3,22k | Vente | 3,00 - 3,07 | 55,92k | -1,86% |
| 2025-08-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,49k | 7,56k | Vente | 3,00 - 3,07 | 124,66k | -1,95% |
| 2025-08-14 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,11k | 36,56k | Vente | 3,02 | 137,05k | -8,12% |
| 2025-08-14 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -7,04k | 21,26k | Vente | 3,02 | 56,98k | -11,00% |
| 2025-08-14 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -11,16k | 33,70k | Vente | 3,02 | 124,23k | -8,24% |
| 2025-07-03 | Mr. Aaron OndreyInitié | -1,48k | 4,26k | Vente | 2,88 | 10,53k | -12,31% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
